Iovance Biotherapeutics

Iovance Biotherapeutics, Inc.
FormerlyLion Biotechnologies, Inc.
TypePublic company
Traded as
  • Nasdaq: IOVA
  • Russell 2000 component
Industry
Founded2007 (2007)
HeadquartersSan Carlos, California, U.S.
Key people
Steven Rosenberg
Number of employees
319 (December 31, 2021)
Websiteiovance.com

Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.[1][2]

History

The company was founded in 2007 as Genesis Biopharma. In 2013, Lion merged with Genesis Biopharma аnd became lion bio Pharma, then rebranded to Iovance in 2017.[3]

Drug pipeline

Iovance has a TIL treatment undergoing clinical trials against melanoma (investigational id: LN-144, tradename: Lifileucel).[4] Iovance is investigating a TIL therapy against cervical and head and neck cancers (investigational id: LN-145).

See also

  • Kite Pharma

References

  1. ↑ Garber, Ken (7 August 2019). "Pursuit of tumor-infiltrating lymphocyte immunotherapy speeds up". Nature Biotechnology. Retrieved 14 August 2019.
  2. ↑ Adelman, Jacob (29 May 2019). "New Navy Yard lab and office complex planned for Calif. cell-therapy research firm Iovance". The Philadelphia Inquirer. Retrieved 14 August 2019.
  3. ↑ "Genesis Biopharma Announces Completion of Merger with Lion Biotechnologies". www.businesswire.com. 2013-07-25. Retrieved 2020-01-17.
  4. ↑ Iovance Biotherapeutics, Inc. (2022-11-14). "An Expanded Access Program of Lifileucel, Autologous Tumor Infiltrating Lymphocytes (TIL; LN-144), for Patients With Unresectable or Metastatic Melanoma". {{cite journal}}: Cite journal requires |journal= (help)
  • Official website
  • Business data for Iovance Biotherapeutics, Inc.:
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.